ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.242,57
-0,05%
S&P 500
5.872,16
-2,95%
Dow Jones
42.326,87
-2,58%
Euro vs US Dollar
1,03794
0,28%
Bitcoin
100.960,12
0,90%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Regulus Therapeutics Inc (RGLS) Börsenkurse

Regulus Therapeutics Inc

Regulus Therapeutics Inc (RGLS)

NASDAQ
1,51
-0,11
(-6,79%)
Geschlossen 19 Dezember 10:00PM
Verzögert um 15 Minuten
1,50
-0,01
(-0,66%)
Nach Börsenschluss: 12:31AM
Verzögert um 15 Minuten

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
1,50
Gebot
1,50
Fragen
1,65
Volumen
232.683
1,50 Tagesbereich 1,64
1,08 52-Wochen-Bereich 3,78
Marktkapitalisierung
98,25M
Handelsende
1,62
Handelsbeginn
1,62
Letzte Trade
500
@
1.5
(formt)
Letzter Handelszeitpunkt
Finanzvolumen
US$ 368.598
VWAP
1,5841
Durchschnittliches Volumen (3 Mio.)
335.021
Ausgegebene Aktien
65.500.134
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-3,29
Gewinn pro Aktie (EPS)
-0,46
Erlöse
-
Nettogewinn
-30,04M

Über Regulus Therapeutics Inc

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The comp... Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.regulusrx.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Regulus Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RGLS. The last closing price for Regulus Therapeutics was US$1,62. Over the last year, Regulus Therapeutics shares have traded in a share price range of US$ 1,08 to US$ 3,78.

Regulus Therapeutics currently has 65.500.134 shares in issue. The market capitalisation of Regulus Therapeutics is US$106,11 million. Regulus Therapeutics has a price to earnings ratio (PE ratio) of -3.29.

RGLS Neueste Nachrichten

Weitere Nachrichten

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences PR Newswire SAN DIEGO, Nov. 26, 2024 SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Regulus Therapeutics Inc...

26 November 2024
PR Newswire (US)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

08 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 November 2024
Edgar (US Regulatory)

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates PR Newswire SAN DIEGO, Nov. 7, 2024 Completed enrollment in the fourth cohort of the Phase 1b...

07 November 2024
PR Newswire (US)

Form 8-K - Current report

24 Oktober 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

24 Oktober 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

11 Oktober 2024
Edgar (US Regulatory)

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant...

08 Oktober 2024
PR Newswire (US)

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences PR Newswire SAN DIEGO, Aug. 28, 2024 SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Regulus Therapeutics Inc...

28 August 2024
PR Newswire (US)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.17-10.17964071861.671.771.53369711.64330539CS
40.085.63380281691.421.771.32550361.58855984CS
12-0.01-0.6622516556291.511.81.33350211.54566751CS
26-0.88-36.9747899162.382.591.35681571.80819728CS
520.1511.11111111111.353.781.0811205972.2207794CS
1561.158338.5964912280.3423.780.15767658771.41001286CS
2600.9015150.6265664160.59853.780.157611757831.17658316CS

RGLS - Frequently Asked Questions (FAQ)

What is the current Regulus Therapeutics share price?
The current share price of Regulus Therapeutics is US$ 1,50
How many Regulus Therapeutics shares are in issue?
Regulus Therapeutics has 65.500.134 shares in issue
What is the market cap of Regulus Therapeutics?
The market capitalisation of Regulus Therapeutics is USD 106,11M
What is the 1 year trading range for Regulus Therapeutics share price?
Regulus Therapeutics has traded in the range of US$ 1,08 to US$ 3,78 during the past year
What is the PE ratio of Regulus Therapeutics?
The price to earnings ratio of Regulus Therapeutics is -3,29
What is the reporting currency for Regulus Therapeutics?
Regulus Therapeutics reports financial results in USD
What is the latest annual profit for Regulus Therapeutics?
The latest annual profit of Regulus Therapeutics is USD -30,04M
What is the registered address of Regulus Therapeutics?
The registered address for Regulus Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Regulus Therapeutics website address?
The website address for Regulus Therapeutics is www.regulusrx.com
Which industry sector does Regulus Therapeutics operate in?
Regulus Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
LITMSnow Lake Resources Ltd
US$ 0,7943
(334,04%)
1,19B
NUKKNukkleus Inc
US$ 50,68
(326,60%)
53,58M
PLRZPolyrizon Ltd
US$ 3,256
(210,10%)
136,74M
QMCOQuantum Corporation
US$ 60,085
(153,31%)
22,59M
VRARGlimpse Group Inc
US$ 3,1885
(100,53%)
54,75M
XCHXCHG Ltd
US$ 2,16
(-90,74%)
11,2M
FTELFitell Corporation
US$ 5,50
(-85,67%)
1,69M
XHGXChange TED Inc
US$ 0,754
(-52,28%)
549,39k
MHUAMeihua International Medical Technologies Company Ltd
US$ 0,2755
(-43,82%)
8,86M
RNAZTransCode Therapeutics Inc
US$ 3,915
(-38,00%)
860,08k
LITMSnow Lake Resources Ltd
US$ 0,7943
(334,04%)
1,19B
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,3671
(9,94%)
312,75M
CGTXCognition Therapeutics Inc
US$ 0,58295
(28,15%)
284,82M
RGTIRigetti Computing Inc
US$ 10,684
(-4,01%)
276,65M
NVDANVIDIA Corporation
US$ 128,91
(-1,14%)
273,75M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
RGLS
Regulus Therapeutics
EU
BE3871294240
Belgian State Bonds
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten